Product Code: 137750-08-22
Urinary tract infection (UTI) is a most common type of infection, it involve infection to the kidneys, ureters, bladder, or urethra. UTI treatment market is rapidly growing due to factors such as growing prevalence of UTI, significant unmet needs, rising number of drug resistant bacteria due to excessive use of antibiotics.
The report titled "Urinary Tract Infection (UTI) Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022-2030" offers strategic insights into the overall UTI treatment market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on drug class (penicillin, quinolones, cephalosporin, sulphonamides, tetracycline and other) and different geographical regions.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global UTI treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global UTI treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global UTI treatment market. In-depth competitive environment analysis and historical years (2021) market size data are also provided in the report.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Urinary Tract Infection (UTI) Treatment market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the Urinary Tract Infection (UTI) Treatment market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Drug Class
Penicillin
Quinolones
Cephalosporin
Sulphonamides
Tetracycline
Other
Region Segment (2020-2030; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Global Impact of COVID-19 Segment (2020-2021; US$ Million )
Pre COVID-19 situation
Post COVID-19 situation
Key questions answered in this report:
What are the key micro and macro environmental factors that are impacting the growth of Urinary Tract Infection (UTI) Treatment market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2030.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Urinary Tract Infection (UTI) Treatment market?
Which is the largest regional market for Urinary Tract Infection (UTI) Treatment market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Urinary Tract Infection (UTI) Treatment market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Urinary Tract Infection (UTI) Treatment market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Urinary Tract Infection (UTI) Treatment Market
- 2.2. Global Urinary Tract Infection (UTI) Treatment Market, By Drug Class, 2021 (US$ Million)
- 2.3. Global Urinary Tract Infection (UTI) Treatment Market, By Geography, 2021 (US$ Million)
- 2.4. Attractive Investment Proposition by Geography, 2021
3. Urinary Tract Infection (UTI) Treatment Market: Competitive Analysis
- 3.1. Market Positioning of Key Urinary Tract Infection (UTI) Treatment Market Vendors
- 3.2. Strategies Adopted by Urinary Tract Infection (UTI) Treatment Market Vendors
- 3.3. Key Industry Strategies
- 3.4. Tier Analysis 2021 Versus 2030
4. Urinary Tract Infection (UTI) Treatment Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Urinary Tract Infection (UTI) Treatment Market Value, 2020 - 2030, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
5. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2021 Versus 2030
- 5.3. Market Segmentation
- 5.3.1. Penicillin
- 5.3.2. Quinolones
- 5.3.3. Cephalosporin
- 5.3.4. Sulphonamides
- 5.3.5. Tetracycline
- 5.3.6. Other
6. North America Urinary Tract Infection (UTI) Treatment Market, 2020-2030, USD (Million)
- 6.1. Market Overview
- 6.2. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 6.3.Urinary Tract Infection (UTI) Treatment Market: By Region, 2020-2030, USD (Million)
- 6.3.1.North America
- 6.3.1.1. U.S.
- 6.3.1.1.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 6.3.1.2. Canada
- 6.3.1.2.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 6.3.1.3. Rest of North America
- 6.3.1.3.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
7. UK and European Union Urinary Tract Infection (UTI) Treatment Market, 2020-2030, USD (Million)
- 7.1. Market Overview
- 7.2. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 7.3.Urinary Tract Infection (UTI) Treatment Market: By Region, 2020-2030, USD (Million)
- 7.3.1.UK and European Union
- 7.3.1.1. UK
- 7.3.1.1.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 7.3.1.2. Germany
- 7.3.1.2.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 7.3.1.3. Spain
- 7.3.1.3.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 7.3.1.4. Italy
- 7.3.1.4.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 7.3.1.5. France
- 7.3.1.5.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 7.3.1.6. Rest of Europe
- 7.3.1.6.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
8. Asia Pacific Urinary Tract Infection (UTI) Treatment Market, 2020-2030, USD (Million)
- 8.1. Market Overview
- 8.2. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 8.3.Urinary Tract Infection (UTI) Treatment Market: By Region, 2020-2030, USD (Million)
- 8.3.1.Asia Pacific
- 8.3.1.1. China
- 8.3.1.1.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 8.3.1.2. Japan
- 8.3.1.2.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 8.3.1.3. India
- 8.3.1.3.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 8.3.1.4. Australia
- 8.3.1.4.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 8.3.1.5. South Korea
- 8.3.1.5.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 8.3.1.6. Rest of Asia Pacific
- 8.3.1.6.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
9. Latin America Urinary Tract Infection (UTI) Treatment Market, 2020-2030, USD (Million)
- 9.1. Market Overview
- 9.2. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 9.3.Urinary Tract Infection (UTI) Treatment Market: By Region, 2020-2030, USD (Million)
- 9.3.1.Latin America
- 9.3.1.1. Brazil
- 9.3.1.1.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 9.3.1.2. Mexico
- 9.3.1.2.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 9.3.1.3. Rest of Latin America
- 9.3.1.3.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
10. Middle East and Africa Urinary Tract Infection (UTI) Treatment Market, 2020-2030, USD (Million)
- 10.1. Market Overview
- 10.2. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 10.3.Urinary Tract Infection (UTI) Treatment Market: By Region, 2020-2030, USD (Million)
- 10.3.1.Middle East and Africa
- 10.3.1.1. GCC
- 10.3.1.1.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 10.3.1.2. Africa
- 10.3.1.2.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
- 10.3.1.3. Rest of Middle East and Africa
- 10.3.1.3.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
11. Company Profile
- 11.1. AstraZeneca plc.
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Portfolio
- 11.1.4. Strategic Initiatives
- 11.2. Bayer AG
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Portfolio
- 11.2.4. Strategic Initiatives
- 11.3. Cubist Pharmaceuticals
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Portfolio
- 11.3.4. Strategic Initiatives
- 11.4. F. Hoffmann-La Roche Ltd.
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Portfolio
- 11.4.4. Strategic Initiatives
- 11.5. GlaxoSmithKline Pharmaceuticals Ltd.
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Portfolio
- 11.5.4. Strategic Initiatives
- 11.6. Johnson & Johnson
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Portfolio
- 11.6.4. Strategic Initiatives
- 11.7. MerLion Pharmaceuticals
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Portfolio
- 11.7.4. Strategic Initiatives
- 11.8. Osel Inc.
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Portfolio
- 11.8.4. Strategic Initiatives
- 11.9. Pfizer Inc.
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Portfolio
- 11.9.4. Strategic Initiatives
- 11.10. Rempex Pharmaceuticals
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Portfolio
- 11.10.4. Strategic Initiatives